阿米万他单抗和卡铂-培美曲塞联合疗法的研究,与卡铂-培美曲塞相比,在以表皮生长因子受体 (EGFR) 外显子 20 插入为特征的晚期或转移性非小细胞肺癌参与者中的研究 (PAPILLON)
61186372NSC3001: A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.
研究概览
研究类型
注册 (实际的)
阶段
- 第三阶段
扩展访问
联系人和位置
学习地点
-
-
-
Beijing、中国、100142
- Beijing Cancer Hospital
-
Beijing、中国、100853
- Chinese PLA General Hospital
-
Beijing、中国、102206
- Peking University International Hospital
-
Beijing、中国、100142
- Beijing Cancer Hospital Chest Tumor Internal Medicine dept. II
-
Beijing、中国、101199
- Beijing Chest hospital, Capital medical university
-
Changchun、中国、130000
- Jilin cancer hospital
-
Changsha、中国、410013
- Hunan Cancer Hospital Chest Tumor Internal Medicine dept. II
-
Changsha、中国、410013
- Hunan Cancer hospital
-
Changzhou、中国、213003
- The First People's Hospital Of Changzhou
-
Chengdu、中国、610041
- West China Hospital Sichuan University
-
Chongqing、中国、400030
- Chongqing University Cancer Hospital
-
Fuzhou、中国、350001
- Fujian Medical University Union Hospital
-
Guangzhou、中国、510080
- The First Affiliated Hospital Sun Yat sen University
-
Hangzhou、中国、310022
- Zhejiang Cancer Hospital
-
Hangzhou、中国、310009
- The Second Affiliated Hospital of Zhejiang University College of Medicine
-
Hangzhou、中国、310003
- The First Affiliated Hospital Zhejiang University College of Medicine
-
Hangzhou、中国、310016
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine
-
Hangzhou、中国、310009
- The Second Affiliated Hospital of Zhejiang University College of Medicine 1
-
Harbin、中国、150000
- Harbin medical university cancer hospital
-
Linhai、中国、317000
- Taizhou Hospital of Zhejiang Province
-
Nanjing、中国、210031
- Nanjing Drum Tower Hospital
-
Shanghai、中国、200030
- Shanghai Chest Hospital
-
Shanghai、中国、200032
- Fudan University Shanghai Cancer Center
-
Shanghai、中国、200433
- Shanghai Pulmonary Hospital
-
Shanghai、中国、200123
- Shanghai East Hospital
-
Shenyang、中国、110004
- Shengjing Hospital Of China Medical University
-
Shenzhen、中国、518116
- Cancer hospital Chinese Academy of Medical Sciences, Shenzhen Center
-
Tianjin、中国、300052
- Tianjin Medical University General Hospital
-
Weifang、中国、261000
- Weifang People's Hospital
-
Wuhan、中国、430030
- TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology
-
Wuxi、中国、214122
- Hospital of Jiangnan University
-
Xi'an、中国、710061
- The First Affiliated Hospital of Xian Jiaotong University
-
Yantai、中国、264000
- Yantai Yuhuangding Hospital
-
Zhengzhou、中国、450008
- Henan Cancer Hospital
-
-
-
-
-
Dnipro、乌克兰、49102
- Dnipropetrovsk State Medical Academy, Dnipropetrovsk City Multifield Clinical Hospital # 4
-
Kyiv、乌克兰、02091
- Medical Center 'Ok Clinic' of LLC 'International Institute of Clinical Studies'
-
Kyiv、乌克兰、03022
- National Cancer Institute
-
-
-
-
-
Jerusalem、以色列、91031
- Shaare Zedek Medical Center
-
Jerusalem、以色列、9112001
- Hadassah Medical Center
-
Kfar Saba、以色列、44281
- Meir Medical Center
-
Petah Tikva、以色列、49100
- Rabin Medical Center
-
Tel Aviv、以色列、6423906
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Irkutsk、俄罗斯、664035
- Irkutsk Regional Oncology Dispensary
-
Krasnogorsk、俄罗斯、143423
- Moscow City Oncology Hospital No 62
-
Krasnoyarsk、俄罗斯、660133
- Krasnoyarsk Regional Oncology Dispensary
-
Kuzmolovsky、俄罗斯、188663
- Leningrad Regional Oncology Dispensary
-
Moscow、俄罗斯、115533
- MCK
-
Nal'chik、俄罗斯、360000
- City Clinical Hospital #1
-
Nizhny Novgorod、俄罗斯、603000
- Nizhny Novgorod Regional Oncological Dispensary
-
Saint Petersburg、俄罗斯、197758
- N.N. Petrov Research Institute Of Oncology
-
Saint Petersburg、俄罗斯、194291
- Leningrad Regional Clinical Hospital
-
Saint Petersburg、俄罗斯、196006
- Oncology Medical Clinics AV Medical group
-
Tomsk、俄罗斯、634050
- Tomsk Cancer Research Institute
-
Ufa、俄罗斯、450083
- Bashkir State Medical University
-
Yaroslavl、俄罗斯、150054
- Yaroslavl Regional Clinical Oncology Hospital
-
-
-
-
Ontario
-
Ottawa、Ontario、加拿大、K1H 8L6
- The Ottawa Hospital Cancer Centre
-
Toronto、Ontario、加拿大、M4N 3M5
- Sunnybrook Health Sciences Centre
-
-
Quebec
-
Montreal、Quebec、加拿大、H4A 3J1
- McGill University Health Centre
-
-
-
-
-
Budapest、匈牙利、H-1529
- Orszagos Koranyi Tbc es Pulmonologiai Intezet
-
Gyöngyös、匈牙利、3233
- Mátrai Gyógyintézet-Bronchológia
-
Szombathely、匈牙利、9700
- Markusovszky Egyetemi Oktatokorhaz
-
Székesfehérvár、匈牙利、8000
- Fejer Varmegyei Szent Gyorgy Egyetemi Oktatokorhaz
-
Törökbálint、匈牙利、2045
- Tudogyogyintezet Torokbalint
-
-
-
-
-
Hyderabad、印度、500034
- Basavatarakam Indo-American Hospital
-
Kolkata、印度、700160
- Tata Medical Center
-
Mumbai、印度、400012
- Tata Memorial Hospital
-
Nashik、印度、422002
- HCG Manavta Cancer Centre
-
New Delhi、印度、110085
- Rajiv Gandhi Cancer Institute & Research Centre
-
Pune、印度、411013
- Noble Hospital Pvt Ltd
-
-
-
-
-
Kaohsiung City、台湾、807
- Kaohsiung Medical University Chung Ho Memorial Hospital
-
Kaohsiung City、台湾、833
- Chang Gung Medical Foundation
-
New Taipei City、台湾、23561
- Taipei Medical University Shuang Ho Hospital
-
Taichung、台湾、40447
- China Medical University Hospital
-
Taichung、台湾、402
- Chung Shan Medical University Hospital
-
Taipei、台湾、10002
- National Taiwan University Hospital
-
-
-
-
-
Adana、土耳其(türkiye)、01060
- Adana City Hospital
-
Adana、土耳其(türkiye)、01250
- Başkent University Medical Faculty Adana Application and Research Center
-
Ankara、土耳其(türkiye)、6560
- Gazi University Hospital
-
Ankara、土耳其(türkiye)、6800
- Ankara Bilkent City Hospital
-
Edirne、土耳其(türkiye)、22030
- Trakya University Medical Faculty
-
Istanbul、土耳其(türkiye)、34722
- Goztepe Prof Dr Suleyman Yalcin Sehir Hastanesi
-
Istanbul、土耳其(türkiye)、34098
- Istanbul Universitesi Cerrahpasa Tip Fakultesi Ic Hastaliklari Anabilim Dali Medikal Onkoloji Bd
-
Istanbul、土耳其(türkiye)、34214
- Medipol Mega University Hospital
-
Izmir、土耳其(türkiye)、35580
- Izmir Medical Park Hospital
-
-
-
-
-
Chihuahua City、墨西哥、31217
- Centro Oncologico de Chihuahua
-
Guadalajara、墨西哥、44280
- Hospital Civil de Guadalajara Fray Antonio Alcalde
-
Mexico City、墨西哥、14080
- Instituto Nacional de Cancerologia
-
Mexico City、墨西哥、14050
- Médica Sur
-
Mexico City、墨西哥、03100
- Mexico Centre for Clinical Research, S.A. de C.V.
-
Monterrey、墨西哥、64710
- i Can Oncology Center
-
México、墨西哥、03100
- Health Pharma Professional Research
-
Naucalpan、墨西哥、53100
- Oncologia Integral Satelite
-
-
-
-
-
Barretos、巴西、14784-400
- Fundacao Pio XII
-
Belo Horizonte、巴西、30110-017
- Cetus Oncologia
-
Florianópolis、巴西、88020-210
- Ynova Pesquisa Clinica
-
Ijuí、巴西、98700-000
- Oncosite - Centro de Pesquisa Clínica em Oncologia Ltda
-
Natal、巴西、59062 000
- Liga Norte Riograndense Contra O Cancer
-
Pelotas、巴西、96020 080
- UPCO Unidade de Pesquisa Clinica em Oncologia
-
Porto Alegre、巴西、90020-090
- Irmandade Santa Casa de Misericordia de Porto Alegre
-
Porto Alegre、巴西、90610-000
- Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS
-
Rio de Janeiro、巴西、22 250 905
- Oncoclinicas Rio de Janeiro S A
-
Rio de Janeiro、巴西、22281 100
- Instituto D Or de Pesquisa e Ensino IDOR
-
Rio de Janeiro、巴西、20231 050
- Ministerio da Saude Instituto Nacional do Cancer
-
Sorocaba、巴西、18030-075
- IOS - Instituto de Oncologia de Sorocaba Dr. Gilson Delgado
-
São Paulo、巴西、04014-002
- Núcleo de Pesquisa São Camilo
-
São Paulo、巴西、01509 900
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo、巴西、01246 000
- Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
-
Vitória、巴西、29308-014
- Hospital Evangélico de Cachoeiro de Itapemirim
-
-
-
-
-
Bad Berka、德国、99437
- Zentralklinik Bad Berka GmbH
-
Berlin、德国、13125
- Evangelische Lungenklinik Berlin
-
Cologne、德国、50937
- Universitaetsklinikum Koeln
-
Cologne、德国、51109
- Kliniken der Stadt Koeln gGmbH
-
Gauting、德国、82131
- Asklepios Klinik Gauting GmbH - Asklepios Fachkliniken Munchen-Gauting
-
Heidelberg、德国、69126
- Thoraxklinik am Universitatsklinikum Heidelberg
-
Heilbronn、德国、74072
- Onkologische Schwerpunktpraxis
-
Moers、德国、47441
- Bethanien Krankenhaus
-
Oldenburg、德国、26121
- Pius-Hospital Oldenburg
-
Recklinghausen、德国、45659
- Oncologianova GmbH
-
-
-
-
-
Bologna、意大利、40138
- A O U Sant Orsola Malpighi
-
Catania、意大利、95123
- Azienda Ospedaliero Univ. Policlinico Gaspare Rodolico
-
Meldola、意大利、47014
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
-
Milan、意大利、20132
- IRCCS Ospedale San Raffaele
-
Milan、意大利、20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Milan、意大利、20122
- Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
-
Monza、意大利、20052
- San Gerardo Hospital
-
Ravenna、意大利、48121
- Ospedale S. Maria Delle Croci
-
Roma、意大利、00168
- Irccs Gemelli
-
Rozzano、意大利、20089
- Istituto Clinico Humanitas
-
-
-
-
-
Bunkyō City、日本、113 8431
- Juntendo University Hospital
-
Hidaka、日本、350-1298
- Saitama Medical University International Medical Center
-
Himeji、日本、670-8520
- National Hospital Organization Himeji Medical Center
-
Hirakata、日本、573 1191
- Kansai Medical University Hospital
-
Kanazawa、日本、920 8641
- Kanazawa University Hospital
-
Kashiwa、日本、277 8577
- National Cancer Center Hospital East
-
Kishiwada、日本、596-8501
- Kishiwada City Hospital
-
Kobe、日本、650-0047
- Kobe City Medical Center General Hospital
-
Kurashiki、日本、710-8602
- Kurashiki Central Hospital
-
Kurume、日本、830-0011
- Kurume University Hospital
-
Matsusaka、日本、515-8544
- Matsusaka Municipal Hospital
-
Nagoya、日本、460-0001
- National Hospital Organization Nagoya Medical Center
-
Nagoya、日本、464 8681
- Aichi Cancer Center Hospital
-
Niigata、日本、951-8566
- Niigata Cancer Center Hospital
-
Osaka Sayama Shi、日本、589 8511
- Kindai University Hospital
-
Sagamihara、日本、252-0375
- Kitasato University Hospital
-
Sapporo、日本、060-8648
- Hokkaido University Hospital
-
Shiwa-gun、日本、028-3695
- Iwate Medical University Hospital
-
Shizuoka、日本、411 8777
- Shizuoka Cancer Center
-
Tokyo、日本、135 8550
- The Cancer Institute Hospital of JFCR
-
Toon-shi、日本、791-0295
- Ehime University Hospital
-
Wakayama、日本、641 8510
- Wakayama Medical University Hospital
-
Yamaguchi、日本、755-0241
- National Hospital Organization Yamaguchi Ube Medical Center
-
-
-
-
-
Leuven、比利时、3000
- UZ Leuven
-
Roeselare、比利时、8800
- Algemeen Ziekenhuis Delta
-
Yvoir、比利时、5530
- CHU UCL Namur - Site Godinne
-
-
-
-
-
Bordeaux、法国、33000
- Institut Bergonie
-
Bron、法国、69500
- Hospices Civils de Lyon HCL
-
Dijon、法国、21000
- Centre Georges Francois Leclerc
-
Le Mans、法国、72037
- Centre Hospitalier Le Mans
-
Lille、法国、59037
- CHR Hôpital Calmette
-
Nantes、法国、44093
- CHU Nantes - Hopital Nord Laënnec
-
Paris、法国、75005
- Institut Curie
-
Pessac、法国、33604
- CHU Bordeaux
-
Saint-Mandé、法国、94163
- HIA Begin
-
-
-
-
-
Bydgoszcz、波兰、85 796
- Centrum Onkologii im Prof F Lukaszczyka
-
Gdansk、波兰、80 214
- Uniwersyteckie Centrum Kliniczne
-
Gdynia、波兰、81 519
- Szpitale Pomorskie Sp z o o
-
Olsztyn、波兰、10-357
- Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie
-
Poznan、波兰、60-693
- Private Specialist Hospitals - MedPolonia
-
Warsaw、波兰、02-781
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
-
-
-
-
-
Rio Piedras、波多黎各、00935
- Pan American Center for Oncology Trials LLC
-
-
-
-
-
Bangkok、泰国、10700
- Siriraj Hospital
-
Bangkok、泰国、10400
- Phramongkutklao Hospital and Medical College
-
Songkhla、泰国、90110
- Songklanagarind Hospital, Prince of Songkla University
-
-
-
-
-
Camperdown、澳大利亚、2050
- Chris O'Brien Lifehouse
-
Kogarah、澳大利亚、2217
- St George Hospital
-
Malvern、澳大利亚、3144
- Cabrini Medical Centre
-
Nedlands、澳大利亚、6009
- Sir Charles Gairdner Hospital
-
-
-
-
California
-
Duarte、California、美国、91010
- City of Hope 2
-
Orange、California、美国、92868
- University of California Irvine
-
Santa Monica、California、美国、90404
- UCLA
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20007
- Georgetown University Hospital
-
-
Florida
-
Tampa、Florida、美国、33612
- H. Lee Moffitt Cancer & Research Institute
-
-
Georgia
-
Athens、Georgia、美国、30607
- University Cancer And Blood Center LLC
-
-
Michigan
-
Detroit、Michigan、美国、48202
- Henry Ford Hospital
-
-
Missouri
-
St Louis、Missouri、美国、63110
- Washington University Medical Center
-
-
New Jersey
-
East Brunswick、New Jersey、美国、08816
- Regional Cancer Care Associates LLC
-
-
New York
-
New York、New York、美国、10032
- Columbia University Medical Center
-
New York、New York、美国、10016
- Langone Health at NYC University, NYU School of Medicine
-
-
Oregon
-
Portland、Oregon、美国、97213
- Providence Portland Medical Center
-
-
South Dakota
-
Sioux Falls、South Dakota、美国、57104
- Sanford Health
-
-
Texas
-
Tyler、Texas、美国、75702
- Texas Oncology Pa
-
-
Utah
-
Salt Lake City、Utah、美国、84106
- Utah Cancer Specialists
-
-
Virginia
-
Fairfax、Virginia、美国、22031
- Virginia Cancer Specialists
-
Salem、Virginia、美国、24153
- Blue Ridge Cancer Care
-
-
-
-
-
Edinburgh、英国、EH4 2XU
- Edinburgh Cancer Centre Western General
-
London、英国、SW3 6JJ
- The Royal Marsden NHS Trust Chelsea
-
Sutton、英国、SM2 5PT
- The Royal Marsden NHS Trust Sutton
-
-
-
-
-
Lisbon、葡萄牙、G1R 2J6
- Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos
-
Lisbon、葡萄牙、1998-018
- Hosp. Cuf Descobertas
-
Porto、葡萄牙、4200-072
- Instituto Portugues de Oncologia
-
Porto、葡萄牙、4099-001
- Centro Hospitalar Universitario do Porto, EPE
-
Vila Nova de Gaia、葡萄牙、4434 502
- Centro Hospitalar de Vila Nova de Gaia Espinho E P E
-
-
-
-
-
A Coruña、西班牙、15006
- Hosp Univ A Coruna
-
Badalona、西班牙、08916
- Inst. Cat. D'Oncologia-Badalona
-
Barcelona、西班牙、08025
- Hosp. de La Santa Creu I Sant Pau
-
Barcelona、西班牙、08028
- Hosp. Univ. Quiron Dexeus
-
Barcelona、西班牙、08035
- Hosp Univ Vall D Hebron
-
Burgos、西班牙、09003
- Hosp. Univ. de Burgos
-
Madrid、西班牙、28041
- Hosp. Univ. 12 de Octubre
-
Madrid、西班牙、28034
- Hosp. Univ. Ramon Y Cajal
-
Madrid、西班牙、28046
- Hosp. Univ. La Paz
-
Madrid、西班牙、28007
- Hosp. Gral. Univ. Gregorio Maranon
-
Majadahonda、西班牙、28222
- Hosp. Univ. Pta. de Hierro Majadahonda
-
Málaga、西班牙、29010
- Hosp Virgen de La Victoria
-
Pamplona、西班牙、31008
- Clinica Univ. de Navarra
-
Seville、西班牙、41013
- Hosp. Virgen Del Rocio
-
Zaragoza、西班牙、50009
- Hosp. Clinico Univ. Lozano Blesa
-
-
-
-
-
Busan、韩国、48108
- Inje University Haeundae Paik Hospital
-
Gyeonggi-do、韩国、10408
- National Cancer Center 1
-
Gyeongsangnam-do、韩国、52727
- GyeongSang National University Hospital
-
Jeollanam-do、韩国、58128
- Chonnam National University Hwasun Hospital
-
Seongnam-si、韩国、13620
- Seoul National University Bundang Hospital
-
Seoul、韩国、05505
- Asan Medical Center
-
Seoul、韩国、03722
- Severance Hospital Yonsei University Health System
-
Seoul、韩国、06351
- Samsung Medical Center
-
Seoul、韩国、03181
- Kangbuk Samsung Hospital
-
Seoul、韩国、02841
- Korea University Anam Hospital
-
Seoul、韩国、06591
- The Catholic University of Korea Seoul St Mary s Hospital
-
-
-
-
-
George Town、马来西亚、10990
- Hospital Pulau Pinang
-
Johor Bahru、马来西亚、81100
- Hospital Sultan Ismail
-
Kuala Lumpur、马来西亚、50586
- Hospital Kuala Lumpur
-
Kuala Lumpur、马来西亚、59100
- University Malaya Medical Centre
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Participant must have histologically or cytologically confirmed, locally advanced or metastatic, nonsquamous non-small cell lung cancer (NSCLC) with documented primary epidermal growth factor receptor (EGFR) Exon 20ins activating mutation
- Participant must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
- Participant must have Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Participant must agree to genetic characterization of tumor status through the required pretreatment tumor biopsy (or submission of equivalent archival material), as well as baseline and periodic blood samples for analysis of tumor mutations in the bloodstream
- A female participant of childbearing potential must have a negative serum or urine test at screening and within 72 hours of the first dose of study treatment and must agree to further serum or urine pregnancy tests during the study
Exclusion Criteria:
- Participant has evidence of synchronous NSCLC disease (as suggested by genetic characterization or radiographic appearance)
- Participant has untreated brain metastases (a participant with definitively, locally treated metastases who is clinically stable, asymptomatic, and off corticosteroid treatment for at least 2 weeks prior to randomization is eligible)
- Participant has history of spinal cord compression that has not been treated definitively with surgery or radiation
- Participant has a medical history of interstitial lung disease (ILD), including drug-induced ILD, or radiation pneumonitis
- Participant has a contraindication to the use of carboplatin or pemetrexed (refer to local prescribing information for each agent). Participant has a history of hypersensitivity to, or cannot take, vitamin B12 or folic acid
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Arm A: Amivantamab + Chemotherapy
Participants will receive pemetrexed 500 milligram per meter square (mg/m^2) intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression. Carboplatin area under the concentration-time curve 5 milligram per milliliter (mg/mL) per minute (AUC 5) will be administered as IV infusion on Day 1 of each 21 day cycle, for up to 4 cycles. Participants will receive amivantamab 1400 mg (1750 mg if body weight is >=80 kilogram [kg]) by IV infusion once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is >=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3. Following the primary analysis for efficacy, the study will transition to an OLE phase and participants will continue to receive the amivantamab plus chemotherapy in OLE phase. Participants who completed OLE period will enter LTE period and continue to receive same treatment. |
Amivantamab will be administered as an IV infusion at a dose of 1400 mg (1750 mg if body weight is >=80 kilogram [kg]) by once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is >=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3 and will continue the same treatment in OLE phase then in LTE phase.
其他名称:
Pemetrexed will be administered as 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm A and will continue the same treatment in OLE phase then in LTE phase. Carboplatin will be administered as AUC 5 IV infusion for up to 4 cycles on Day 1 of each 21-day cycle. Pemetrexed will be administered as 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm B and will continue the same treatment in OLE phase then in LTE phase. |
|
实验性的:Arm B: Chemotherapy Alone
Participants will receive pemetrexed 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression. Carboplatin AUC 5 IV infusion will be administered on Day 1 of each 21-day cycle for up to 4 cycles. Following the primary analysis for efficacy, the study will transition to an OLE phase and participants will either continue to receive the chemotherapy or cross over to amivantamab in OLE phase. Participants who completed OLE period will enter LTE period and continue to receive same treatment. |
Pemetrexed will be administered as 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm A and will continue the same treatment in OLE phase then in LTE phase. Carboplatin will be administered as AUC 5 IV infusion for up to 4 cycles on Day 1 of each 21-day cycle. Pemetrexed will be administered as 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm B and will continue the same treatment in OLE phase then in LTE phase. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)
大体时间:From randomization to either disease progression or death whichever occurs first (up to 29 months)
|
PFS was defined as the time from randomization until the date of objective disease progression based on BICR using RECIST version 1.1 or death (by any cause) in the absence of progression, whichever came first. Participants who have not progressed or have not died at the time of analysis were censored at the time of the latest date of their last evaluable RECIST version 1.1 assessment. Pharmacodynamic: Sum of diameters increased by greater than or equal to (>=)20 percent (%) and >=5 millimeter (mm) from nadir (including baseline if it was smallest sum). |
From randomization to either disease progression or death whichever occurs first (up to 29 months)
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
客观缓解率 (ORR)
大体时间:最长5年3个月
|
最长5年3个月
|
|
响应持续时间 (DoR)
大体时间:最长5年3个月
|
最长5年3个月
|
|
总生存期 (OS)
大体时间:最长5年3个月
|
最长5年3个月
|
|
后续治疗时间 (TST)
大体时间:最长5年3个月
|
最长5年3个月
|
|
首次后续治疗后的无进展生存期 (PFS2)
大体时间:最长5年3个月
|
最长5年3个月
|
|
症状进展时间 (TTSP)
大体时间:最长5年3个月
|
最长5年3个月
|
|
参与者数量 治疗中出现的不良事件 (TEAE)
大体时间:从第 1 天到 5 年 2 个月
|
从第 1 天到 5 年 2 个月
|
|
严重程度 TEAE 的参与者数量
大体时间:从第 1 天到 5 年 2 个月
|
从第 1 天到 5 年 2 个月
|
|
临床实验室异常的参与者人数
大体时间:最长5年3个月
|
最长5年3个月
|
|
生命体征异常的参与者人数
大体时间:最长5年3个月
|
最长5年3个月
|
|
体检异常人数
大体时间:最长5年3个月
|
最长5年3个月
|
|
阿米凡他单抗的血清浓度
大体时间:第 1 天(第 1、2、3、5、7、9、11、13 周期)、第 2 天(第 1 周期)
|
第 1 天(第 1、2、3、5、7、9、11、13 周期)、第 2 天(第 1 周期)
|
|
具有抗阿米万他抗体的参与者人数
大体时间:第 1 天(第 1、2、3、5、7、9、11、13 周期)、第 2 天(第 1 周期)
|
第 1 天(第 1、2、3、5、7、9、11、13 周期)、第 2 天(第 1 周期)
|
|
欧洲癌症研究和治疗组织生活质量问卷核心 30 (EORTC-QLQ-C30) 相对于基线的变化
大体时间:从基线到 5 年 3 个月
|
从基线到 5 年 3 个月
|
|
患者报告结果测量信息系统 - 身体功能 (PROMIS-PF) 相对于基线的变化
大体时间:从基线到 5 年 3 个月
|
从基线到 5 年 3 个月
|
合作者和调查者
调查人员
- 研究主任:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC
出版物和有用的链接
一般刊物
- Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, Sanborn RE, Mansfield AS, Hung JY, Boyer M, Popat S, Mourao Dias J, Felip E, Majem M, Gumus M, Kim SW, Ono A, Xie J, Bhattacharya A, Agrawal T, Shreeve SM, Knoblauch RE, Park K, Girard N; PAPILLON Investigators. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023 Nov 30;389(22):2039-2051. doi: 10.1056/NEJMoa2306441. Epub 2023 Oct 21.
- Sanborn RE, Zhou C, Tang KJ, Cho BC, Cheng S, Popat S, Ono A, Lu S, Majem M, Aguilar A, Del Rosario Garcia Campelo M, Hayashi H, Lee KY, Lee SH, Delmonte A, Alatorre-Alexander J, Richardson G, Santos V, Dooms C, Sabari JK, Shu CA, Girard N, Mansfield AS, Park K, Xia Y, Bhattacharya A, Buyukkaramikli N, Perualila N, Diels J, Acharya S, Chandler C, Proskorovsky I, Dearden L, Wortman-Vayn H, Mahadevia PJ, Knoblauch RE, Agrawal T, Baig M, Felip E. Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study. Target Oncol. 2025 Nov;20(6):979-989. doi: 10.1007/s11523-025-01182-0. Epub 2025 Nov 3.
- Kitazono S, Ono A, Kawamura T, Hataji O, Tanaka H, Matsumoto S, Watanabe N, Nagashima H, Oki M, Takahashi M, Anazawa T, Shirai T, Yamashita A, Wortman-Vayn H, Bhattacharya A, Agrawal T, Baig M, Knoblauch RE, Hayashi H. Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC. Cancer Sci. 2025 Nov;116(11):3139-3148. doi: 10.1111/cas.70180. Epub 2025 Sep 8.
- Zhou C, Tang KJ, Liu B, Kim SW, Kitazono S, Ono A, Thiagarajan M, Hung JY, Boyer M, CIl T, Yao Y, Nagarkar R, Xie J, Bhattacharya A, Wortman-Vayn H, Baig M, Agrawal T, Lorenzini P, Lee SH, Cho BC. Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis. Lung Cancer. 2026 Mar;213:109302. doi: 10.1016/j.lungcan.2026.109302. Epub 2026 Feb 2.
- Tang K, Wu F, Yang F, Yao Y, Zhao Y, Zhou J, Sun P, Wang D, Lv D, Wang H, Hu Y, Li Q, Song Y, Gao G, Pan F, Bhattacharya A, Baig M, Lorenzini PA, Wortman-Vayn H, Agrawal T, Zhou C. Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trial. Chin Med J (Engl). 2026 May 26. doi: 10.1097/CM9.0000000000004134. Online ahead of print.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- CR108850
- 61186372NSC3001 (其他标识符:Janssen Research & Development, LLC)
- 2023-506033-29-00 (注册表标识符:EUCT number)
- 2023 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.